FDA TO REPORT TO COSMETICS FIRMS ON PRODUCTS WITH ABOVE-NORMAL ADVERSE REACTION
This article was originally published in The Rose Sheet
Executive Summary
FDA TO REPORT TO COSMETICS FIRMS ON PRODUCTS WITH ABOVE-NORMAL ADVERSE REACTION rates based on data obtained from a planned FDA cosmetics adverse reaction hotline. A Nov. 10 Federal Register notice announced that FDA is seeking clearance from the Office of Management and Budget to set up a hotline program designed "to enable the public to report directly to FDA any adverse reactions they encounter with cosmetic product usage."